Skip to main content

Official Journal of the Human Genome Organisation

Table 4 Association between BRCA mutation carriers and breast cancer pathology

From: Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer

 

BRCA mutations‡

Carriers (N = 28) *

Non-Carriers (N = 239) *

  

Unadjusted

n

Col %

n

Col %

χ2

P-value

OR†

95% CI

LVI (Lymphatic invasion):

 Absent/suspiciousa

20

90.9

107

64.5

  

1.00**

 

 Present

2

9.9

59

35.5

6.20

0.01

0.18

(0.04, 0.80)

Grade:

 1 and 2

9

37.5

103

60.6

  

1.00**

 

 3

15

62.5

67

39.4

4.59

0.03

2.56

(1.06, 6.19)

Type:

DCIS (Ductal carcinoma In Situ)

8

23.5

33

15.2

  

1.00**

 

Invasive

26

76.5

84

84.8

1.49

0.22

0.58

(0.24, 1.40)

Stage:

 Stage 0

8

25.8

32

15.7

    

 Stage 1

10

32.3

56

27.5

  

1.00**

 

 Stage 2, 3, and 4

13

41.9

116

56.9

1.80

0.30

0.63

(0.26, 1.52)

T stage (Tumor size):

 T0

8

24.2

30

14.6

    

 T1

16

48.5

74

36.1

  

1.00**

 

 T2, 3 and 4

9

27.3

84

41.0

6.50

0.05

0.41

(0.17, 0.98)

N stage (Lymph node involvement):

 N0

22

75.9

130

64.0

  

1.00**

 

 N1, 2, and 3

7

24.1

73

36.0

1.57

0.21

0.57

(0.23, 1.39)

M stage (Metastatic):

 M0

32

100.0

201

95.7

    

 M1

0

0

9

4.3

1.42

0.23

ER (Estrogen receptor):

 Positive

15

48.4

141

72.3

  

1.00**

 

 Negative

16

51.6

54

27.7

7.16

0.007

2.78

(1.28, 5.88)

PR (Progesterone receptor):

 Positive

11

36.7

112

58.6

  

1.00**

 

 Negative

19

63.3

79

41.4

5.07

0.02

2.44

(1.10, 5.56)

Cerb 2 (Protein of HER2 Oncogene):

 Positive

9

31.0

87

49.2

  

1.00**

 

 Negative

20

69.0

90

50.8

3.29

0.07

2.13

(0.93,5.00)

Triple negative (ER/PR/Cerb2):

 No

15

51.7

131

74.4

  

1.00**

 

 Yes

14

48.3

45

25.6

6.26

0.01

2.11

(1.22, 5.88)

Ki67 index (% of growing cells):

 <12%

6

60.0

28

50.9

  

1.00**

 

 >12%

4

40.0

27

49.1

0.28

0.60

0.69

(0.18,2.70)

  1. aThere were two BRCA non-carriers and two BRCA carriers with LVI suspicious
  2. Bold figure: Significant at <0.05
  3. * Values may not sum to 100% because of missing data
  4. ** Referent
  5. ‡ Includes 41 bilateral cancers in non-mutation carriers (14%) and 9 bilateral cancers in mutation carriers (24%)
  6. † Univariate Odd Ratios comparing “Carriers” versus “Non-carriers” (reference group)